Rooptaz Sibia, MD
Internal Medicine · Boynton Beach, FLNPI 1770501868
Payments from drug & device makers
Across 310 payments — averaging $79.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$18K
- Novo Nordisk$967
- BD$650
- Pfizer$596
- Kowa Pharmaceuticals America, Inc.$483
- AstraZeneca$445
- plus $4K from 35 others
What the payments were for
- Consulting fees$6599%
- Speaking & faculty fees$3625%
- Food & beverage$5,92985%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi US Services Inc. | 6 | $17,845 |
| Novo Nordisk | 52 | $967 |
| BD | 2 | $650 |
| Pfizer | 30 | $596 |
| Kowa Pharmaceuticals America, Inc. | 22 | $483 |
| AstraZeneca | 19 | $445 |
| Astellas Pharma US Inc | 19 | $387 |
| Mckesson Medical-surgical, Inc. | 1 | $362 |
| AbbVie(2 entities) | 19 | $357 |
| Bayer | 13 | $273 |
| Amarin Pharma, Inc. | 15 | $262 |
| Exact Sciences | 11 | $240 |
| Atricure, Inc. | 4 | $215 |
| Johnson & Johnson | 12 | $206 |
| GSK | 11 | $199 |
| Lilly USA, LLC | 8 | $152 |
| Kvk-tech, Inc. | 15 | $140 |
| Boston Scientific | 6 | $123 |
| Novartis | 7 | $120 |
| Merck | 8 | $117 |
| Amgen | 6 | $112 |
| Medtronic | 1 | $52 |
| Edwards Lifesciences | 2 | $51 |
| Stryker | 1 | $44 |
| Smith+Nephew | 1 | $44 |
| Sumitomo Pharma America, Inc. | 2 | $41 |
| Genentech USA, Inc. | 2 | $32 |
| Boehringer Ingelheim | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Biohaven Pharmaceuticals, Inc. | 1 | $25 |
| Abbott | 1 | $24 |
| Insightec,inc | 1 | $24 |
| Biosense Webster, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,795 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 169 | $202,052 |
| EliquisApixaban | 155 | $167,410 |
| XareltoRivaroxaban | 121 | $132,839 |
| JanuviaSitagliptin Phosphate | 59 | $66,277 |
| FarxigaDapagliflozin Propanediol | 52 | $42,791 |
| MounjaroTirzepatide | 18 | $35,837 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $35,239 |
| RybelsusSemaglutide | 20 | $34,750 |
| MyrbetriqMirabegron | 20 | $26,271 |
| JardianceEmpagliflozin | 23 | $22,263 |
| EntrestoSacubitril/Valsartan | 15 | $21,682 |
| InvokanaCanagliflozin | 18 | $14,774 |
| Rosuvastatin Calcium | 1,049 | $12,664 |
| SynthroidLevothyroxine Sodium | 206 | $12,195 |
| Levothyroxine Sodium | 1,029 | $11,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $967 | $236,802189 claims |
| PfizerEliquis, Paxlovid | $596 | $172,993217 claims |
| Johnson & JohnsonXarelto, Invokana | $206 | $147,612139 claims |
| MerckJanuvia | $117 | $66,27759 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $199 | $44,39841 claims |
| AstraZenecaFarxiga | $445 | $42,79152 claims |
| Lilly USA, LLCMounjaro | $152 | $35,83718 claims |
| Astellas Pharma US IncMyrbetriq | $387 | $26,27120 claims |
| Boehringer IngelheimJardiance | $27 | $22,26323 claims |
| NovartisEntresto | $120 | $21,68215 claims |
| AbbVieSynthroid | $357 | $12,195206 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $11,8171,029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Boynton Beach
- Debra WeinsteinBoynton Beach$14.8M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.